Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.36
BRLI's Cash to Debt is ranked lower than
79% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. BRLI: 0.36 )
Ranked among companies with meaningful Cash to Debt only.
BRLI' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.31 Max: 1.39
Current: 0.36
0.02
1.39
Equity to Asset 0.66
BRLI's Equity to Asset is ranked higher than
60% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BRLI: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
BRLI' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.56 Max: 0.73
Current: 0.66
0.33
0.73
Interest Coverage 34.11
BRLI's Interest Coverage is ranked lower than
66% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. BRLI: 34.11 )
Ranked among companies with meaningful Interest Coverage only.
BRLI' s 10-Year Interest Coverage Range
Min: 0.85  Med: 12.73 Max: 52.32
Current: 34.11
0.85
52.32
F-Score: 6
Z-Score: 7.96
M-Score: -2.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.14
BRLI's Operating margin (%) is ranked higher than
74% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. BRLI: 10.14 )
Ranked among companies with meaningful Operating margin (%) only.
BRLI' s 10-Year Operating margin (%) Range
Min: -6.49  Med: 8.92 Max: 12.39
Current: 10.14
-6.49
12.39
Net-margin (%) 5.74
BRLI's Net-margin (%) is ranked higher than
72% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. BRLI: 5.74 )
Ranked among companies with meaningful Net-margin (%) only.
BRLI' s 10-Year Net-margin (%) Range
Min: -9.28  Med: 5.60 Max: 8.27
Current: 5.74
-9.28
8.27
ROE (%) 16.15
BRLI's ROE (%) is ranked higher than
85% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. BRLI: 16.15 )
Ranked among companies with meaningful ROE (%) only.
BRLI' s 10-Year ROE (%) Range
Min: -35.97  Med: 18.37 Max: 24.15
Current: 16.15
-35.97
24.15
ROA (%) 10.56
BRLI's ROA (%) is ranked higher than
86% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. BRLI: 10.56 )
Ranked among companies with meaningful ROA (%) only.
BRLI' s 10-Year ROA (%) Range
Min: -13.68  Med: 10.76 Max: 14.14
Current: 10.56
-13.68
14.14
ROC (Joel Greenblatt) (%) 30.75
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. BRLI: 30.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21.79  Med: 31.61 Max: 43.4
Current: 30.75
-21.79
43.4
Revenue Growth (3Y)(%) 14.70
BRLI's Revenue Growth (3Y)(%) is ranked higher than
78% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. BRLI: 14.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BRLI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.3  Med: 16.30 Max: 22.4
Current: 14.7
1.3
22.4
EBITDA Growth (3Y)(%) 10.50
BRLI's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. BRLI: 10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BRLI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.1  Med: 23.60 Max: 37.3
Current: 10.5
-18.1
37.3
EPS Growth (3Y)(%) 9.20
BRLI's EPS Growth (3Y)(%) is ranked higher than
63% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. BRLI: 9.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BRLI' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.8  Med: 22.00 Max: 196.2
Current: 9.2
-61.8
196.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BRLI Guru Trades in Q3 2014

John Hussman 59,000 sh (+18.00%)
Paul Tudor Jones 21,700 sh (+10.06%)
Chase Coleman 720,000 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 58,000 sh (-0.85%)
Chuck Royce 280,900 sh (-7.70%)
» More
Q4 2014

BRLI Guru Trades in Q4 2014

Joel Greenblatt 11,951 sh (New)
Steven Cohen 46,800 sh (New)
Paul Tudor Jones 28,610 sh (+31.84%)
Mario Gabelli 59,000 sh (+1.72%)
Chase Coleman 720,000 sh (unchged)
John Hussman 59,000 sh (unchged)
Chuck Royce 206,300 sh (-26.56%)
» More
Q1 2015

BRLI Guru Trades in Q1 2015

John Hussman 203,000 sh (+244.07%)
Chuck Royce 289,100 sh (+40.14%)
Joel Greenblatt 13,925 sh (+16.52%)
Mario Gabelli 65,000 sh (+10.17%)
Chase Coleman Sold Out
Steven Cohen Sold Out
Paul Tudor Jones 21,100 sh (-26.25%)
» More
Q2 2015

BRLI Guru Trades in Q2 2015

John Hussman 203,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.03
BRLI's P/E(ttm) is ranked higher than
68% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. BRLI: 24.03 )
Ranked among companies with meaningful P/E(ttm) only.
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34  Med: 21.77 Max: 35.69
Current: 24.03
9.34
35.69
PE(NRI) 25.10
BRLI's PE(NRI) is ranked higher than
67% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. BRLI: 25.10 )
Ranked among companies with meaningful PE(NRI) only.
BRLI' s 10-Year PE(NRI) Range
Min: 9.33  Med: 21.73 Max: 35.91
Current: 25.1
9.33
35.91
P/B 3.64
BRLI's P/B is ranked lower than
54% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. BRLI: 3.64 )
Ranked among companies with meaningful P/B only.
BRLI' s 10-Year P/B Range
Min: 1.77  Med: 3.78 Max: 5.8
Current: 3.64
1.77
5.8
P/S 1.39
BRLI's P/S is ranked higher than
78% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. BRLI: 1.39 )
Ranked among companies with meaningful P/S only.
BRLI' s 10-Year P/S Range
Min: 0.61  Med: 1.27 Max: 1.98
Current: 1.39
0.61
1.98
PFCF 399.39
BRLI's PFCF is ranked lower than
98% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. BRLI: 399.39 )
Ranked among companies with meaningful PFCF only.
BRLI' s 10-Year PFCF Range
Min: 16.27  Med: 92.20 Max: 958
Current: 399.39
16.27
958
POCF 44.37
BRLI's POCF is ranked lower than
79% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. BRLI: 44.37 )
Ranked among companies with meaningful POCF only.
BRLI' s 10-Year POCF Range
Min: 11.04  Med: 34.64 Max: 197.75
Current: 44.37
11.04
197.75
EV-to-EBIT 14.02
BRLI's EV-to-EBIT is ranked higher than
75% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. BRLI: 14.02 )
Ranked among companies with meaningful EV-to-EBIT only.
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9  Med: 13.10 Max: 22.1
Current: 14.02
5.9
22.1
PEG 1.43
BRLI's PEG is ranked higher than
81% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. BRLI: 1.43 )
Ranked among companies with meaningful PEG only.
BRLI' s 10-Year PEG Range
Min: 0.36  Med: 0.90 Max: 1.82
Current: 1.43
0.36
1.82
Shiller P/E 30.98
BRLI's Shiller P/E is ranked lower than
55% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. BRLI: 30.98 )
Ranked among companies with meaningful Shiller P/E only.
BRLI' s 10-Year Shiller P/E Range
Min: 15.23  Med: 33.45 Max: 96.67
Current: 30.98
15.23
96.67
Current Ratio 2.34
BRLI's Current Ratio is ranked lower than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BRLI: 2.34 )
Ranked among companies with meaningful Current Ratio only.
BRLI' s 10-Year Current Ratio Range
Min: 1.11  Med: 1.83 Max: 3.11
Current: 2.34
1.11
3.11
Quick Ratio 2.21
BRLI's Quick Ratio is ranked lower than
52% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. BRLI: 2.21 )
Ranked among companies with meaningful Quick Ratio only.
BRLI' s 10-Year Quick Ratio Range
Min: 1.08  Med: 1.78 Max: 2.9
Current: 2.21
1.08
2.9
Days Inventory 15.61
BRLI's Days Inventory is ranked higher than
83% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. BRLI: 15.61 )
Ranked among companies with meaningful Days Inventory only.
BRLI' s 10-Year Days Inventory Range
Min: 5.94  Med: 7.84 Max: 15.79
Current: 15.61
5.94
15.79
Days Sales Outstanding 118.03
BRLI's Days Sales Outstanding is ranked lower than
85% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. BRLI: 118.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRLI' s 10-Year Days Sales Outstanding Range
Min: 91.06  Med: 114.56 Max: 162.14
Current: 118.03
91.06
162.14

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.05
BRLI's Price/Net Current Asset Value is ranked higher than
61% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. BRLI: 6.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 1.1  Med: 7.00 Max: 50
Current: 6.05
1.1
50
Price/Tangible Book 4.28
BRLI's Price/Tangible Book is ranked higher than
56% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. BRLI: 4.28 )
Ranked among companies with meaningful Price/Tangible Book only.
BRLI' s 10-Year Price/Tangible Book Range
Min: 0.68  Med: 4.13 Max: 9
Current: 4.28
0.68
9
Price/Projected FCF 3.00
BRLI's Price/Projected FCF is ranked lower than
64% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. BRLI: 3.00 )
Ranked among companies with meaningful Price/Projected FCF only.
BRLI' s 10-Year Price/Projected FCF Range
Min: 1.91  Med: 3.66 Max: 62.5
Current: 3
1.91
62.5
Price/DCF (Earnings Based) 0.88
BRLI's Price/DCF (Earnings Based) is ranked higher than
92% of the 13 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.91 vs. BRLI: 0.88 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.10
BRLI's Price/Median PS Value is ranked lower than
51% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. BRLI: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 0.84 Max: 1.81
Current: 1.1
0.11
1.81
Price/Peter Lynch Fair Value 1.76
BRLI's Price/Peter Lynch Fair Value is ranked higher than
57% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. BRLI: 1.76 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61  Med: 0.94 Max: 1.4
Current: 1.76
0.61
1.4
Price/Graham Number 2.15
BRLI's Price/Graham Number is ranked higher than
64% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. BRLI: 2.15 )
Ranked among companies with meaningful Price/Graham Number only.
BRLI' s 10-Year Price/Graham Number Range
Min: 0.3  Med: 2.04 Max: 5.26
Current: 2.15
0.3
5.26
Earnings Yield (Greenblatt) (%) 7.08
BRLI's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. BRLI: 7.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BRLI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.5  Med: 7.60 Max: 17
Current: 7.08
4.5
17
Forward Rate of Return (Yacktman) (%) 14.49
BRLI's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.12 vs. BRLI: 14.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BRLI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.9  Med: 26.45 Max: 34.9
Current: 14.49
0.9
34.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:BFR.Germany,
Bio-Reference Laboratories Inc is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It also offers laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The Company is engaged in esoteric testing, molecular diagnostics, anatomical pathology, genetics, womens health and correctional health care. The Company has a network of approximately 116 patient service centers located in the Northeast (in New York metropolitan super-regional area) for collection of patient specimens. It conducts business in New York State counties, as well as in New Jersey, Maryland, Pennsylvania, Delaware and Connecticut. It offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, phlebotomy services and phlebotomy draw stations. The Company operates a clinical knowledge management service through its PSIMedica business unit. The system uses customer data from laboratory results, pharmaceutical data, claims data and other data sources provide administrative and clinical decision support systems that enable customers to provide quality and efficient healthcare to their populations. It also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its competitors in the New York metropolitan area are Quest Diagnostics (DGX) and Laboratory Corporation of America (LH). The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.
» More Articles for BRLI

Headlines

Articles On GuruFocus.com
Small cap high short interest (Predictability = 5), Part 1 Oct 16 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
DaVita Seems to be a High-Growth Company Aug 20 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
4 Attractive Small-Cap Growth + Value Stocks You Have Never Heard Of Apr 16 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 
Historical Short Interest Of Stocks – New Feature Announcement Jan 17 2014 
New Feature Announcement: Stocks With The Highest Short Interest Dec 12 2013 
comment on BRLI May 11 2013 

More From Other Websites
OPKO's Prostate Cancer Hit Jul 23 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 05 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Bio-Reference Laboratories, Inc.... Jul 01 2015
Barron's Recap: Airline Stocks Ready To Soar Jun 21 2015
Misgivings About a Health-Care Merger Jun 19 2015
Lifshitz & Miller Law Firm Announces Investigation of Bio-Reference Laboratories, Inc., DARA... Jun 16 2015
BRLI INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Jun 16 2015
INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Bio-Reference Laboratories,... Jun 15 2015
BIO REFERENCE LABORATORIES INC Financials Jun 12 2015
BRLI INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Jun 12 2015
10-Q for Bio-Reference Laboratories, Inc. Jun 11 2015
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jun 11 2015
The Proposed Acquisition Of Bio-Reference Laboratories, Inc Is Under Investigation By The Young Law... Jun 11 2015
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Jun 10 2015
BRLI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Jun 09 2015
BIO REFERENCE LABORATORIES INC Files SEC form 10-Q, Quarterly Report Jun 09 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Bio-Reference... Jun 08 2015
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK